case-control study demonstrates receipt of HER2-targeted therapy during pregnancy resulted in significantly higher reports of fetal oligohydramnios (OR 17.68), congenital respiratory tract disorders (OR 9.98), neonatal kidney failure (OR 9.15), intrauterine growth restriction (OR 7.68), and cardiovascular malformation (OR 4.46) when compared to receipt of other antineoplastic agents during pregnancy. | Gougis, JAMA Netw Open 2023
